GlassScriptPhysician profile
Gemma A Ciesemier
NPI 1093790966
$2,764.15
in general payments reported to CMS, 2019-2025
29 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $122 · 2021: $1,241 · 2022: $623 · 2023: $385 · 2024: $61.85 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $573.73 | 2021-2025 | Cuvitru, Hyqvia, Takhzyro |
| Abbvie INC. | $341.21 | 2021-2022 | |
| Horizon Therapeutics Plc | $227.27 | 2020-2023 | Actimmune |
| Grifols USA, LLC | $191.35 | 2019-2023 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $189.71 | 2020-2022 | |
| Csl Behring | $136.71 | 2021-2023 | Haegarda, Hizentra |
| Novo Nordisk INC | $133.79 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $108.47 | 2019-2023 | Fasenra |
| Amgen INC. | $91.65 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.34 | 2021-2022 | |
| Mylan Specialty L.P. | $78.78 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $70.98 | 2019-2022 | |
| Genzyme Corporation | $67.92 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $65.56 | 2021 | |
| Novartis Pharmaceuticals Corporation | $46.42 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $44.84 | 2021-2022 | |
| Pfizer INC. | $39.98 | 2020-2021 | |
| Genentech, INC. | $38.45 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $32.67 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $29.10 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.44 | 2021 | |
| Lilly USA, LLC | $24.94 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.03 | 2022 | |
| Genentech USA, INC. | $20.91 | 2023 | Xolair |
| Sunovion Pharmaceuticals INC. | $14.79 | 2019 | |
| Organogenesis INC. | $14.41 | 2021 | |
| Optos, INC. | $13.87 | 2021 | |
| Astellas Pharma US INC | $12.98 | 2019 | |
| Amarin Pharma, INC. | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gemma Ciesemier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.